You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide
SBC: OUI THERAPEUTICS INC Topic: 104ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Pigment Sensing Pulse Oximeter Technology for Mitigating Racial Bias in Oxygen Saturation Measurements
SBC: PENDERIA TECHNOLOGIES, INC. Topic: 100Abstract Wearable pulse oximetry sensors are among the most ubiquitous medical technologies used in healthcare. Clinicians rely on pulse oximeters to monitor patient health during disease states and medical procedures. However, numerous studies have shown this technology to be racially biased; hypoxemia is three times more likely to go undetected in patients with dark skin compared to those with l ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Agents Targeting Cryptococcal Infections
SBC: Quercus Molecular Design, LLC Topic: NIAIDCryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Leptospirosis Vaccine Development
SBC: Luna Bioscience, Inc. Topic: NIAIDSummary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Treatment for Alcohol-associated Liver Disease
SBC: MITOTHERAPEUTIX, LLC Topic: 350Abstract The Specific Aim of this Phase I TTR proposal is to test the feasibility of our siRNA drug to ameliorate the pathology and progression of alcohol-associated liver disease (ALD). Alcohol consumption remains a leading cause of hepatic pathology worldwide and is one of the greatest sources of preventable morbidity and mortality. In the U.S., alcohol abuse impacts over 10 million individuals ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers
SBC: BORROW MY GLASSES LLC Topic: NIA1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Making Mindfulness-Based Cognitive Therapy accessible for underserved pregnant people: Developing Center M for commercialization
SBC: CENTER MOM, INC. Topic: 104PROJECT SUMMARY/ABSTRACT A highly effective intervention to prevent perinatal depression, mindfulness-based cognitive therapy for perinatal depression (MBCT), exists; however, critical implementation gaps prevent its wide use. And though universally recommended, not all prenatal care clinics effectively screen for perinatal depression (PD). Overcoming current implementation gaps is imperative to a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
SBC: Gamma Therapeutics, Inc. Topic: NHLBIPROJECT SUMMARY/ABSTRACT g' (pronounced "gamma prime") fibrinogen (GPF) is an alternative splice isoform of the blood coagulation factor fibrinogen. This fibrinogen variant contains a high affinity binding site for the coagulation factor thrombin that localizes thrombin on the growing blood clot. Thrombin binds to GPF via thrombin's heparin binding site. This allows thrombin to continue forming th ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Self-Guided Mobile Intervention for Adults with Binge Eating and Obesity
SBC: OUI THERAPEUTICS INC Topic: 104ABSTRACT Obesity and comorbid binge eating are serious health problems for more than 40% of adults across the US.7 Health complications due to obesity comprise more than 20% of the nation’s healthcare budget, and the healthcare costs of individuals with binge eating are $18,152 higher than in obese peers without binge eating.13 The prevalence of binge eating and the substantial burden of healthc ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An adjustable stiffness orthosis to maintain muscle engagement and push-off power in cerebral palsy.
SBC: BIOMOTUM, INC. Topic: NICHDPROJECT SUMMARY/ABSTRACT Ankle foot orthoses (AFOs) are commonly prescribed to improve mobility for individuals with neurological disorders. AFOs are included in the standard of care for the majority of ambulatory children with cerebral palsy (CP), a pediatric-onset movement disorder caused by insult to the developing brain. Current goals of treatment for individuals with CP center around increasi ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health